1.46 USD
+0.03
2.10%
Updated Mar 17, 1:49 PM EDT
1 day
2.10%
5 days
6.57%
1 month
-1.35%
3 months
14.96%
6 months
-48.59%
Year to date
-24.74%
1 year
-81.95%
5 years
-82.41%
10 years
-98.44%
 

About: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

Employees: 143

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

7% more funds holding

Funds holding: 14 [Q3] → 15 (+1) [Q4]

4.38% less ownership

Funds ownership: 10.3% [Q3] → 5.92% (-4.38%) [Q4]

56% less capital invested

Capital invested by funds: $1.7M [Q3] → $752K (-$946K) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for EVGN.

Financial journalist opinion

Based on 4 articles about EVGN published over the past 30 days

Neutral
Seeking Alpha
1 week ago
Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
Evogene Ltd. (NASDAQ:EVGN ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Ofer Haviv - President and CEO Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's Fourth Quarter Results Conference Call.
Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 week ago
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
PRNewsWire
1 week ago
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel , March 6, 2025 /PRNewswire/ -- Evogene Ltd.
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025
Neutral
PRNewsWire
3 weeks ago
Evogene Schedules Fourth Quarter 2024 Financial Results Release
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel , Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025.
Evogene Schedules Fourth Quarter 2024 Financial Results Release
Neutral
PRNewsWire
1 month ago
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
Neutral
Seeking Alpha
3 months ago
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Ltd. (NASDAQ:EVGN ) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Amit Noam - CEO, Lavie BIO Operator Welcome to Evogene's Third Quarter Results Conference Call.
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
3 months ago
Evogene Reports Third Quarter 2024 Financial Results
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023. In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023.
Evogene Reports Third Quarter 2024 Financial Results
Neutral
PRNewsWire
3 months ago
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel , Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd.
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Neutral
PRNewsWire
4 months ago
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season   REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Neutral
PRNewsWire
4 months ago
Evogene Schedules Third Quarter 2024 Financial Results Release
Zoom conference call scheduled for November 21, 2024, 9:00 AM ET REHOVOT, Israel , Nov. 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024.
Evogene Schedules Third Quarter 2024 Financial Results Release
Charts implemented using Lightweight Charts™